<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1498">
  <stage>Registered</stage>
  <submitdate>16/03/2007</submitdate>
  <approvaldate>26/06/2007</approvaldate>
  <actrnumber>ACTRN12607000338460</actrnumber>
  <trial_identification>
    <studytitle>A study to compare the effectiveness and safety of an oral low dose and megadose of cholecalciferol treatment in participants with vitamin D deficiency - a real-life comparison pilot study.</studytitle>
    <scientifictitle>A study to compare the effectiveness and safety of an oral low dose and a megadose vitamin D treatment regimens - a real-life comparison pilot study.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin D deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention will be oral 50,000 IU cholecalciferol daily for 10 days and then weekly for 3 months.</interventions>
    <comparator>The active control will be oral 1000 IU cholecalciferol tablets at a dose of four per day for one month and then one a day for 3 months.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Normalisation of serum 25(0H) concentrations to &gt; 50 nmol/L</outcome>
      <timepoint>At 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety parameters - serum and urine calcium concentrations.</outcome>
      <timepoint>Serum calcium concentrations will be measured at 10 days and 3 months. 24-hour urine calcium concentrations will be measured at 3 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Serum 25(0H) concentration &lt; 50 nmol/L and ability to consent to trial participation. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to either give informed consent or complete the three month study, primary or tertiary hyperparathyroidism or other causes of hypercalcaemia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be randomised to either high or low dose treatment groups and stratified according to baseline 25(0H)D concentration. Allocation concealment will be achieved by the use of central randomisation by another person using a computer generated table</concealment>
    <sequence>Simple randomisation using a randomisation table created by a computer software programme. Patients will be randomised to either high or low dose treatment groups and stratified according to baseline 25(0H)D concentration.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>19/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof. Peter Ebeling</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Melbourne</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will compare the effectiveness and safety of an oral low dose and a megadose vitamin D treatment regimen - it will be a real-life dose comparison study. This intervention study will have an active control group. The intervention will be oral 50,000 IU cholecalciferol daily for 10 days and then weekly for 3 months. The active comparator will be lower dose oral 1000 IU cholecalciferol tablets at a dose of four per day for one month and then one a day for 3 months. The outcome will be the numbers of subjects in each group achieving an optimal serum vitamin D level at 3 months. Safety measures will also be studied.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Footscray-Approval given by Melbourne Health HREC</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006.104</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sunsine-Approval given by Melbourne Health HREC</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006.104</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Williamstown-Approval given by Melbourne Health HREC</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006.104</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Peter R Ebeling</name>
      <address>Department of Medicine (WH/RMH),
University of Melbourne,
Western Hospital, Footscray</address>
      <phone>(03) 8345 6429</phone>
      <fax>(03) 9318 1157</fax>
      <email>peterre@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. Peter R. Ebeling</name>
      <address>Department of Medicine (WH/RMH),
University of Melbourne,
Western Hospital, Footscray</address>
      <phone>(03) 8345 6429</phone>
      <fax>(03) 9318 1157</fax>
      <email>peterre@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>